|
|
Clinical Efficacy of Compound Xuanju Capsule in Treatment of Chronic Prostatitis and the Influence on Serum MIP-2 and SIgA Levels |
WAN Tao, ZHOU Zhijun, LU Tong, et al |
The First People's Hospital of Tianmen, Hubei Tianmen 431700, China |
|
|
Abstract Objective: To investigate the clinical efficacy of compound Xuanju capsule in the treatment of chronic prostatitis and the influence on the serum MIP-2 and SIgA levels. Methods: 130 cases of patients with chronic prostatitis treated from September 2014 to March 2016 in our hospital were selected and divided into the observation group and the control group according to the random number table, with 65 cases in each group. The control group was given a daily moxifloxacin hydrochloride tablets and prostate massage once; the observation group was given complex Xuanju capsules on the basis of control group, three times a day, three tablets each time. The changes of serum MIP-2 and SIgA levels were compared between the two groups before and after treatment. Results: The overall effective rate was significantly higher in the observation group than that in the control group, and the NIH-CPSI score after treatment was significantly lower than that of the control group [(10.93±3.20) vs (19.68±4.27)](P<0.05). The levels of serum MIP-2 and SIgA in both groups were significantly lower than those in the control group before and after treatment, the serum MIP-2 and SIgA levels in the observation group were lower than those in the control group [(4.17±0.61)ng/mL vs (6.20±1.04) ng/mL];[(66.51±40.16) μg/mL vs (91.57±48.06)μg/mL] (P<0.05). The secretion of white blood cells in the two groups was significantly decreased after treatment, and the secretion of the observation group was significantly lower than that of the control group [(15.38±11.39)n/HP vs(21.74±10.59)n/HP] (P<0.05). Conclusion: Compound Xuanju capsule could significantly improve the clinical effect of chronic prostatitis patients, which could promote the recovery of the disease and effectively reduce the expressions of serum MIP-2 and SIgA.
|
|
|
|
|
[1] 杨兴智,郭宇,熊伟,等.中药熏蒸联合盐酸左氧氟沙星治疗ⅢA型前列腺炎(湿热瘀滞证)的临床疗效研究[J].中华男科学杂志,2017,23(2):173~177. [2] 郭宏志,刘云波,曾明月,等.补肾活血利湿类中药复方治疗慢性前列腺炎疗效与安全性的系统评价[J].中国药房,2016,27(30):4241~4244. [3] 袁少英,何超拔,金明昱,等.丹红通精方治疗慢性前列腺炎及其对分泌型IgA、血管细胞黏附分子-1表达的影响[J].中华中医药学刊,2016,34(4):966~969. [4] 柯明辉,张培伦,王鑫,等.前列平胶囊治疗慢性无菌性前列腺炎观察[J].中华中医药杂志,2016,31(6):2161~2163. [5] 孙鹏.ⅢA型慢性前列腺炎患者精液质量与男性不育关系[J].医学与哲学(B),2016,37(5):51~53,59. [6] 熊杰,陈铭,张辉,等.八正散加减方治疗慢性前列腺炎的系统评价[J].辽宁中医杂志,2017,44(3):464~468. [7] 雷雨.小剂量局部胰岛素联合应用重组人表皮生长因子对烧伤大鼠创面MIP-2和MCP-1表达的影响[J].中国现代医学杂志,2015,25(6):28~33. [8] 谢咏梅,王丽媛,高珊,等.口服免疫球蛋白对轮状病毒肠炎患儿肠道SIgA分泌的影响[J].四川大学学报(医学版),2015,46(1):71~74. [9] 崔崎,韩玲,成俊,等.前列腺液中免疫球蛋白、细胞因子及趋化因子水平与慢性前列腺炎的关系[J].现代免疫学,2017,37(5):412~416. |
|
|
|